A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

  • STATUS
    Recruiting
  • participants needed
    18
  • sponsor
    Hepion Pharmaceuticals, Inc.
Send
Updated on 5 August 2020
See if I qualify
fibrosis
hepatic fibrosis
fatty liver
fibroscan
vcte

Summary

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

Description

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects. Study will evaluate the safety and tolerability of a once daily 75mg dose of CRV431 compared to placebo over 28 days of dosing. Pharmacokinetic parameters of CRV431 and its major metabolites and fraction unbound will also be evaluated. Non-invasive antifibrotic bio-markers will be collected and quantified from presumed NASH F2/F3 subjects dosed with 75mg CRV431 or placebo.

Details
Condition Cirrhosis, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Age 18years - 75years
Treatment Placebo, CRV431
Clinical Study IdentifierNCT04480710
SponsorHepion Pharmaceuticals, Inc.
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female between 18 and 75 years of age (inclusive)
Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel
Presumed F2/F3 NASH to include: AST >20 IU/L, Pro-C3 >15.5 ng/mL, enhanced liver fibrosis (ELF) score >9.8, and FibroScan >8.5 kPa values

Exclusion Criteria

Pregnant or breastfeeding or planning to become pregnant during the study period
Known allergy to CRV431, cyclosporine, or any of their inactive ingredients
Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb)
Well documented causes of chronic liver disease according to standard diagnostic procedures to include any history or presence of decompensated cirrhosis
Subjects with a platelet count <150,000/mL
Subjects with hemoglobin A1c(HbA1c) >9.5%
Weight loss of more than 5% within 3 months prior to randomization
Subjects with a blood pressure to include a systolic pressure >150 or a diastolic pressure >90\
At Screening, an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 mL (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method) and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of >G2
Subjects with a history of organ transplantation. Corneal transplantation will be allowed
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

fibrosis
hepatic fibrosis
fatty liver
fibroscan
vcte

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.